Cell Therapeutics' Pixuvri gets final NICE recommendation

U.K. health-cost regulator NICE has given a final recommendation for the use of Cell Therapeutics' (CTIC) Pixuvri for treating advanced B-cell non-Hodgkin lymphoma.

Cell Therapeutics now hopes that NHS commissioners "will recognize the lack of suitable treatment options that exist for patients at this stage of the disease and list Pixuvri on hospital formularies as soon as possible."

Cell Therapeutics expects to launch Pixuvri in England and Wales in the spring.

Shares are +8.3%. (PR)

From other sites
Comments (1)
  • bonifax
    , contributor
    Comments (36) | Send Message
    Exactly as I wrote in February 5 comments posted by you
    and counts remain those already 'done. Many think of a retracement of the title after the rise of 1 dollar in July 2013 to about $ 4 today forgetting cge, when the Dow was below 11,000 points, the title is not considering the subsequent reverse split was valued more 'alti.A those times still knew nothing positive about Pacritinib, Tosedostat, Enlistment for Opaxio ended sucessfully. YOU KNEW NOTHING of SUCCESS for pixantrone in Europe (Germany, France, Italy) and now every success in England with guidelines that recommend Nice pixantrone the third and fourth linea.Ripeto still the title and 'STRONGLY Underrated. I wrote about when it was quoted at a
    1,0, $ and the facts have given me reason against detractors of the title. Who gave me a straight has gained more than 300%!!
    2 Mar 2014, 09:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs